Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
  • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
  • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
  • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D307/32—Oxygen atoms

Definitions

• the invention relates to deuterated substituted
• rofecoxib (EP 705254, US 5474995), which is used as a selective COX-2 inhibitor, among other things, for the treatment of symptoms of irritable states of degenerative joint diseases, acute pain in adults and primary dysmenorrhea.
• the object of the present invention is to provide substituted dihydrofuranones which have improved pharmacokinetic and / or pharmacodynamic properties compared to the already known compounds.
• the deuterated substituted dihydrofuranones according to the invention have significantly better pharmacokinetic and / or pharmacodynamic properties than the undeuterated compounds.
• R 1 is methyl or partially or completely deuterated methyl
• R 2 is independently H or D
• R 3 is independently H or D
• R 4 is independently H or D and at least one of the radicals R 1 to R 4 D is or contains D.
• Deuterated substituted dihydrofuranones according to the general formula I are preferred, in which R 1 is partially or completely deuterated methyl, R 2 is independently H or D, R 3 is independently H or D and R 4 is independently H or D.
• deuterated substituted dihydrofuranones according to the general formula I, in which R 1 is methyl or partially or completely deuterated methyl, R 2 is D, R 3 is independently H or D and R 4 is independently H or D.
• deuterated substituted dihydrofuranones according to the general formula I, in which R 1 is methyl or partially or completely deuterated methyl, R 2 is independently H or D, R 3 is D and R 4 is independently H or D.
• R is independently H or D and R is D.
• Deuterated substituted dihydrofuranones according to the general formula I in which R 1 is partially or completely deuterated methyl, R 2 is D, R 3 is independently H or D and R 4 is independently H or D are advantageous.
• Deuterated substituted dihydrofuranones according to the general formula I in which R 1 is partially or completely deuterated methyl, R 2 independently of one another is H or D, R 3 is D and R 4 is independently H or D are particularly advantageous.
• deuterated substituted dihydrofuranones according to the general formula I, in which R 1 is partially or completely deuterated methyl, R 2 is independently H or D, R 3 is independently H or D and R 4 is D.
• Deuterated substituted dihydrofuranones according to the general formula I in which R 1 is methyl or partially or completely deuterated are preferred according to the invention Is methyl, R 2 and R 3 are D and R is independently H or D.
• R 1 is methyl or partially or fully deuterated methyl
• R 2 is D
• R 3 is independently H or D
• R 4 is D.
• R 1 is methyl or partially or completely deuterated methyl
• R 2 are, independently of one another, H or are particularly preferred
• D means and R 3 and R 4 are D
• Deuterated substituted dihydrofuranones according to general formula I are advantageous, in which R 1 is partially or completely deuterated methyl, R 2 and R 3 are D and R 4 is independently H or D.
• Deuterated substituted dihydrofuranones according to the general formula I in which R 1 is partially or completely deuterated methyl, R 2 is D, R 3 is independently H or D and R 4 D are particularly advantageous.
• Deuterated substituted dihydrofuranones according to the general formula I in which R 1 is partially or completely deuterated methyl, R 2 independently of one another is H or D and R 3 and R 4 are D are particularly advantageous.
• Deuterated substituted dihydrofuranones according to general formula I are preferred, wherein R 1 is methyl or is partially or fully deuterated methyl and R 2 , R 3 and R 4 mean D.
• Deuterated substituted dihydrofuranones according to the general formula I are particularly preferred, wherein R 1 is partially or completely deuterated methyl and R 2 , R 3 and R 4 are D.
• deuterated substituted dihydrofuranones according to general formula I and their physiologically tolerable salts, for the treatment of symptoms in irritable states of degenerative joint diseases, of acute pain and primary dysmenorrhea.
• Formula I and its physiologically tolerable salts for the production of medicaments for the treatment of symptoms in irritable states of degenerative joint diseases, of acute pain and primary dysmenorrhea.
• compositions which contain deuterated substituted dihydrofuranones according to general formula I and their physiologically tolerable salts for the treatment of Symptoms of irritable states of degenerative joint diseases, acute pain and primary dysmenorrhea, in addition to pharmaceutically contractual auxiliaries and / or additives.
• the deuterated substituted dihydrofuranones according to the invention are prepared in part by known preparation processes for deuterated
• Dimethyl sulfate or deuterated dimethyl sulfate is S-methylated analogously to EP 206677.
• the deuterated methyl sulfide is then by Friedel-Crafts acylation, for example analogous to Cutler et al. (Journal of the American Chemical Society, Vol. 74, pp. 5475-5481, 1952) converted from optionally deuterated acetyl chloride to deuterated 4- (methylthio) acetophenone. From this, deuterated 4- (methylsulfonyl) acetophenone is obtained by oxidation, for example analogously to EP 705254.
• deuterated 4- (methylsulfonyl) acetophenone is via deuterated 4-chloroacetophenone, which can be obtained from deuterated chlorobenzene by Friedel-Crafts acylation. This ethanone is optionally deuterated
• Sodium methanethiolate for example analogously to JP 8143534, converted to the deuterated 4- (methylthio) acetophenone.
• the deuterated sodium methane thiolate can be obtained analogously to DE 1804266 from deuterated methyl sulfide by reaction with NaOH.
• Dihydrofuranones can be used with customary physiologically compatible inorganic and organic acids. Examples include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, oxalic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, malic acid, citric acid, salicylic acid, adipic acid and benzoic acid. Other acids that can be used are, for example, in Progress in Pharmaceutical Research, Vol. 10, pages 224-225, Birkhauser Verlag, Basel and Stuttgart, 1966, and Journal of Pharmaceutical Sciences, Vol. 66, pages 1-5 (1977).
• the acid addition salts are generally in a manner known per se by mixing the free base or its solutions with the corresponding acid or its solutions in an organic solvent, for example a lower alcohol such as methanol, ethanol, n-propanol or isopropanol or a lower ketone such as Acetone, methyl ethyl ketone or methyl isobutyl ketone or an ether such as diethyl ether, tetrahydrofuran or dioxane. Mixtures of the solvents mentioned can also be used for better crystal deposition.
• physiologically compatible aqueous solutions of acid addition salts of the compounds used according to the invention can be prepared in an aqueous acid solution.
• Compounds can be made in a manner known per se, e.g. B. with alkalis or ion exchangers, are converted into the free base. Additional salts can be obtained from the free base by reaction with inorganic or organic acids, in particular those which are suitable for forming therapeutically usable salts. These or other salts of the new compound, such as. B. the picrate, can also be used to purify the free base by converting the free base into a salt, separating this and in turn releasing the base from the salt.
• the present invention also relates to medicinal products for oral, rectal, topical (percutaneous, transdermal, local), subcutaneous, intravenous or intramuscular application which, in addition to conventional carriers and diluents, contain a compound of the general formula I or its acid addition salt as active ingredient.
• the medicaments of the invention are produced in a known manner with the customary solid or liquid carriers or diluents and the commonly used pharmaceutical-technical auxiliaries in accordance with the desired type of application with a suitable dosage.
• the preferred preparations are in a dosage form which is suitable for oral administration.
• dosage forms are, for example, tablets, film-coated tablets, coated tablets, capsules, pills, powders, solutions or suspensions or depot forms.
• Topical application can take place, for example, in the form of ointments, creams, gels, solutions or by plasters.
• parenteral preparations such as injection solutions are also suitable.
• Suppositories may also be mentioned as preparations.
• Corresponding tablets can be obtained, for example, by mixing the active ingredient with known auxiliaries, for example inert diluents such as dextrose,
• the tablets can also consist of several layers.
• coated tablets can be coated, for example, by coating cores produced analogously to the tablets with agents conventionally used in coated tablet coatings
• Polyvinyl pyrrolidone or shellac, gum arabic, talc, titanium dioxide or sugar can be produced.
• the coated tablet can also consist of several layers, wherein the auxiliaries mentioned above for the tablets can be used.
• Solutions or suspensions with the active ingredient used according to the invention can additionally taste-improving agents such as saccharin, cyclamate or sugar and z.
• B. contain flavorings such as vanillin or orange extract. They can also contain suspending agents such as sodium carboxymethyl cellulose or preservatives such as p-hydroxybenzoates.
• Capsules containing active ingredients can be produced, for example, by mixing the active ingredient with an inert carrier such as milk sugar or sorbitol and encapsulating it in gelatin capsules. Suitable suppositories can be produced, for example, by mixing them with carriers such as neutral fats or polyethylene glycol or their derivatives.
• the preparation of the pharmaceuticals according to the invention for topical application is known to the person skilled in the art.
• the auxiliaries and enhancers known per se are used in the production of the medicaments according to the invention for transdermal use.
• the compounds according to the invention have a number of advantages over the compounds known in the prior art which contain deuterium only in the natural distribution.
• deuteration slows down the metabolism in the organism. This makes it possible to change the dosage and create longer-lasting preparations, which can also improve compliance in the form of depot preparations.

Applications Claiming Priority (3)

Publications (1)

Family

ID=7709639

Family Applications (1)

Country Status (16)

Families Citing this family (19)

Family Cites Families (1)

• 2001
  • 2001-12-12 DE DE10162120A patent/DE10162120A1/de not_active Withdrawn
• 2002
  • 2002-12-11 NZ NZ533596A patent/NZ533596A/en unknown
  • 2002-12-11 IL IL16240602A patent/IL162406A0/xx unknown
  • 2002-12-11 PL PL02369139A patent/PL369139A1/xx not_active Application Discontinuation
  • 2002-12-11 US US10/498,709 patent/US7317039B2/en not_active Expired - Fee Related
  • 2002-12-11 RU RU2004121032/04A patent/RU2004121032A/ru not_active Application Discontinuation
  • 2002-12-11 CN CNA028248287A patent/CN1602304A/zh active Pending
  • 2002-12-11 JP JP2003551126A patent/JP2005511742A/ja active Pending
  • 2002-12-11 CA CA002469519A patent/CA2469519A1/en not_active Abandoned
  • 2002-12-11 EP EP02795002A patent/EP1456192A1/de not_active Withdrawn
  • 2002-12-11 WO PCT/DE2002/004591 patent/WO2003050101A1/de not_active Application Discontinuation
  • 2002-12-11 AU AU2002360900A patent/AU2002360900A1/en not_active Abandoned
  • 2002-12-11 KR KR10-2004-7008699A patent/KR20040088474A/ko not_active Application Discontinuation
  • 2002-12-11 HU HU0402304A patent/HUP0402304A2/hu unknown
• 2004
  • 2004-05-17 IS IS7267A patent/IS7267A/is unknown
  • 2004-07-09 NO NO20042907A patent/NO20042907L/no not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events